Literature DB >> 33687943

Gut microbiota modulates COPD pathogenesis: role of anti-inflammatory Parabacteroides goldsteinii lipopolysaccharide.

Hsin-Chih Lai1,2,3,4,5, Tzu-Lung Lin1, Ting-Wen Chen6,7,8, Yu-Lun Kuo9, Chih-Jung Chang3, Tsung-Ru Wu10, Ching-Chung Shu11, Ying-Huang Tsai3, Simon Swift12, Chia-Chen Lu13,14.   

Abstract

OBJECTIVE: Chronic obstructive pulmonary disease (COPD) is a global disease characterised by chronic obstruction of lung airflow interfering with normal breathing. Although the microbiota of respiratory tract is established to be associated with COPD, the causality of gut microbiota in COPD development is not yet established. We aimed to address the connection between gut microbiota composition and lung COPD development, and characterise bacteria and their derived active components for COPD amelioration.
DESIGN: A murine cigarette smoking (CS)-based model of COPD and strategies evaluating causal effects of microbiota were performed. Gut microbiota structure was analysed, followed by isolation of target bacterium. Single cell RNA sequencing, together with sera metabolomics analyses were performed to identify host responsive molecules. Bacteria derived active component was isolated, followed by functional assays.
RESULTS: Gut microbiota composition significantly affects CS-induced COPD development, and faecal microbiota transplantation restores COPD pathogenesis. A commensal bacterium Parabacteroides goldsteinii was isolated and shown to ameliorate COPD. Reduction of intestinal inflammation and enhancement of cellular mitochondrial and ribosomal activities in colon, systematic restoration of aberrant host amino acids metabolism in sera, and inhibition of lung inflammations act as the important COPD ameliorative mechanisms. Besides, the lipopolysaccharide derived from P. goldsteinii is anti-inflammatory, and significantly ameliorates COPD by acting as an antagonist of toll-like receptor 4 signalling pathway.
CONCLUSION: The gut microbiota-lung COPD axis was connected. A potentially benefial bacterial strain and its functional component may be developed and used as alternative agents for COPD prevention or treatment. © Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  immunology; intestinal microbiology

Mesh:

Substances:

Year:  2021        PMID: 33687943     DOI: 10.1136/gutjnl-2020-322599

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  24 in total

1.  Restoration of cefixime-induced gut microbiota changes by a prebiotic blend in a mouse model.

Authors:  Jingyi Yuan; Song Qin; Shanliang Hu; Zhengyi Liu; Yipeng Song; Lili Li
Journal:  Appl Microbiol Biotechnol       Date:  2022-07-02       Impact factor: 5.560

2.  Multi-omics analyses of airway host-microbe interactions in chronic obstructive pulmonary disease identify potential therapeutic interventions.

Authors:  Zhengzheng Yan; Boxuan Chen; Yuqiong Yang; Xinzhu Yi; Mingyuan Wei; Gertrude Ecklu-Mensah; Mary M Buschmann; Haiyue Liu; Jingyuan Gao; Weijie Liang; Xiaomin Liu; Junhao Yang; Wei Ma; Zhenyu Liang; Fengyan Wang; Dandan Chen; Lingwei Wang; Weijuan Shi; Martin R Stampfli; Pan Li; Shenhai Gong; Xia Chen; Wensheng Shu; Emad M El-Omar; Jack A Gilbert; Martin J Blaser; Hongwei Zhou; Rongchang Chen; Zhang Wang
Journal:  Nat Microbiol       Date:  2022-08-22       Impact factor: 30.964

3.  Gut Commensal Parabacteroides goldsteinii MTS01 Alters Gut Microbiota Composition and Reduces Cholesterol to Mitigate Helicobacter pylori-Induced Pathogenesis.

Authors:  Chih-Ho Lai; Tzu-Lung Lin; Mei-Zi Huang; Shiao-Wen Li; Hui-Yu Wu; Ya-Fang Chiu; Chia-Yu Yang; Cheng-Hsun Chiu; Hsin-Chih Lai
Journal:  Front Immunol       Date:  2022-06-30       Impact factor: 8.786

4.  Gut Microbiota Predicts Healthy Late-Life Aging in Male Mice.

Authors:  Shanlin Ke; Sarah J Mitchell; Michael R MacArthur; Alice E Kane; David A Sinclair; Emily M Venable; Katia S Chadaideh; Rachel N Carmody; Francine Grodstein; James R Mitchell; Yangyu Liu
Journal:  Nutrients       Date:  2021-09-21       Impact factor: 6.706

Review 5.  COPD and Gut-Lung Axis: How Microbiota and Host Inflammasome Influence COPD and Related Therapeutics.

Authors:  Ling Qu; Qing Cheng; Yan Wang; Hui Mu; Yunfeng Zhang
Journal:  Front Microbiol       Date:  2022-04-01       Impact factor: 6.064

Review 6.  Leptin in the Respiratory Tract: Is There a Role in SARS-CoV-2 Infection?

Authors:  Andreina Bruno; Giuliana Ferrante; Serena Di Vincenzo; Elisabetta Pace; Stefania La Grutta
Journal:  Front Physiol       Date:  2021-12-22       Impact factor: 4.566

Review 7.  Gut Dysbiosis in Pancreatic Diseases: A Causative Factor and a Novel Therapeutic Target.

Authors:  Tao Zhang; Guangqi Gao; Hafiz Arbab Sakandar; Lai-Yu Kwok; Zhihong Sun
Journal:  Front Nutr       Date:  2022-02-15

Review 8.  Association of Intestinal Microbial Dysbiosis With Chronic Obstructive Pulmonary Disease.

Authors:  Fariha N Ananya; Md Ripon Ahammed; Michael M Fahem; Sunam Kafle; Mahima Viswanathan; Darshi Desai; Radhika Akku; Faryal Khan; Tabata E Hernandez; Supreet K Bala; Shivam Gulati; Natalia Martin; George D Yatzkan; Javier Pérez-Fernández
Journal:  Cureus       Date:  2021-11-07

9.  Xuanbai Chengqi Decoction Ameliorates Pulmonary Inflammation via Reshaping Gut Microbiota and Rectifying Th17/Treg Imbalance in a Murine Model of Chronic Obstructive Pulmonary Disease.

Authors:  Yongan Wang; Na Li; Qiuyi Li; Zirui Liu; Yalan Li; Jingwei Kong; Ruijuan Dong; Dongyu Ge; Jie Li; Guiying Peng
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2021-12-07

10.  Gegen Qinlian Decoction Alleviates Experimental Colitis and Concurrent Lung Inflammation by Inhibiting the Recruitment of Inflammatory Myeloid Cells and Restoring Microbial Balance.

Authors:  Yalan Li; Na Li; Jiajing Liu; Tieshan Wang; Ruijuan Dong; Dongyu Ge; Guiying Peng
Journal:  J Inflamm Res       Date:  2022-02-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.